Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion

Mihajlović, Jovan; Bax, P.; Breugel, Erwin van; Blommestein, Hedwig M.; Hoogendoorn, Mels; Hospes, Wobbe; Postma, Maarten J.

doi:10.1016/j.clinthera.2017.05.342

Cited by 19 publications

(13 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preparation time or pharmacist time per infusion of rituximab was reported in five publications and ranged from 4–40 min (IV) to 2–20 min (SC) [ 66 , 88 , 90 , 91 , 104 ]. One of these publications reported a study that collected relevant data using a survey [ 66 ]; however, data were consistent with those estimated from direct measurement.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting

McCloskey¹,

Ortega²,

Nair³

et al. 2022

PharmacoEconomics Open

View full text Add to dashboard Cite

Background The introduction of human epidermal growth factor receptor 2 (HER2)-targeted treatment options, including dual HER2 blockade, has improved the prognosis for patients with HER2-positive breast cancer (BC) substantially. However, most of these treatments are administered via the intravenous (IV) route, which can present many challenges, such as long infusion and observation times, issues associated with repeated IV access, and increased strain on time and resources of medical centers and healthcare professionals. A fixed-dose combination of pertuzumab and trastuzumab for subcutaneous (SC) injection (pertuzumab, trastuzumab, and hyaluronidase-zzxf (PHESGO ® , F. Hoffmann-La Roche Ltd, Basel, Switzerland; PH FDC SC)) has been approved for use alongside chemotherapy for early-stage and metastatic HER2-positive BC. Objectives This systematic literature review was performed to identify evidence relating to time/resource use and resulting cost differences between SC and IV administration of oncology biologics in a hospital setting, and, ultimately, to inform economic modeling and associated health technology assessment of PH FDC SC. Methods Electronic databases (Embase, MEDLINE, and EconLit) were searched on 9 April 2020. Additional hand searches were performed to identify publications not captured in the electronic database search. Publication screening and data extraction (study characteristics, participants, interventions, costs, and time/resource use) were carried out per the standard Cochrane review methodology. The quality of economic evidence of cost analyses was assessed using the 36-item checklist of the National Institute for Health and Care Excellence Single Technology Appraisal Specification for submission of evidence (January 2015). Results The database search identified 2,740 records, of which 237 underwent full text screening. Full text screening, prioritization of publications about patients with a cancer diagnosis, and the addition of four citations identified during the hand search resulted in 72 final included publications, relating to 71 unique studies. This included 40 publications that described the time/resource use and/or costs associated with SC versus IV trastuzumab administration for the treatment of HER2-positive BC, and 28 publications that described time/resource use and/or costs associated with rituximab SC versus IV administration for the treatment of non-Hodgkin’s lymphoma/follicular lymphoma and diffuse large B-cell lymphoma. The majority of publications showed substantial time savings for preparation and administration of SC versus IV therapy, and cost savings associated with reductions in healthcare professional time and resource use for SC administration. Limitations There was a lack of consensus between publications regarding time and cost measurements. In addition, the search was limited to publications related to ...

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting

McCloskey¹,

Ortega²,

Nair³

et al. 2022

PharmacoEconomics Open

View full text Add to dashboard Cite

show abstract

“…A recent model-based cost-minimization analysis [ 22 ] used the PrefHer time-and-motion study data [ 11 ] and further evidence on SC- and IV-related costs [ 13 – 15 , 20 , 23 , 24 ] to estimate potential mean non-drug cost differences between PH FDC SC and IV pertuzumab and trastuzumab per patient over the standard 18-cycle course in Western Europe and the USA. For Western Europe, the authors considered both costs derived from PH FDC SC and IV pertuzumab and trastuzumab preparation and administration times (such as the costs for patient chair time and HCP time) and cost elements unrelated to time, such as the cost of non-drug consumables.…”

Section: Value Of Ph Fdc Sc To Patients and Healthcare Professionalsmentioning

confidence: 99%

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

et al. 2022

View full text Add to dashboard Cite

Health technology assessments and value frameworks are becoming increasingly important for clinical decision-making. Most of these frameworks, however, focus on value to payers rather than patients and healthcare providers and may ignore other sources of economic value such as patient and physician time cost, impact on productivity, and direct health system costs. This article focusses on fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive breast cancer. We review relevant clinical evidence, examine data on time and resource use of the subcutaneous administration of trastuzumab compared with intravenous treatment and how it can be extrapolated to PH FDC SC, and discuss the value PH FDC SC can bring to patients and healthcare providers. We will also provide our own experiences of PH FDC SC from the healthcare (oncologist, healthcare economist, pharmacist) and patient point of view. The data, combined with our personal experiences, suggest that switching from intravenous pertuzumab and trastuzumab to PH FDC SC could reduce non-drug costs for healthcare providers treating patients with HER2-positive breast cancer through time savings and other economic benefits. Furthermore, PH FDC SC could also save patient time given its shorter administration and post-injection observation time versus intravenous infusions, potentially resulting in reduced productivity loss. These benefits could be applied to other subcutaneous formulations, either currently available or in development.

show abstract

“…SC-R seems to demonstrate a comparable efficacy/safety profile as IV-R. LON incidence was comparable with previous reports [8] . A costing study should be envisaged to demonstrate cost saving as it is the case for diffuse large B-cell lymphoma [9] . Finally, it may be possible to give the first dose subcutaneously rather than intravenously, even without premedication, as it was reported recently for lymphoma cases [10] .…”

Section: Discussionmentioning

confidence: 99%

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

Péterlin¹,

Guillaume²,

Garnier³

et al. 2018

Leukemia Research Reports

View full text Add to dashboard Cite

Microcosting Study of Rituximab Subcutaneous Injection Versus Intravenous Infusion

Cited by 19 publications

References 14 publications

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting

A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting

White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases

Contact Info

Product

Resources

About